7333 Does Allgrove Syndrome Have Endocrine Manifestations Beyond Adrenal Insufficiency?

Mikaela Jara-Tantoco,Catherine Anastasopoulou,Sri Ram Teja Sathi
DOI: https://doi.org/10.1210/jendso/bvae163.1040
2024-10-01
Journal of the Endocrine Society
Abstract:Abstract Disclosure: S. Sathi: None. M. Jara-Tantoco: None. C. Anastasopoulou: None. Background: Allgrove syndrome, initially described as a triad of alacrimia, adrenal insufficiency (AI), and esophageal achalasia (Triple A syndrome) is a multisystem disorder with a wide array of phenotypic presentations. Mutations involving the AAAS (achalasia-addisonianism-alacrimia syndrome) gene on chromosome 12q13 are the cause with a prevalence of 1 in 1 million population. To our knowledge, there are no reports of any other endocrine manifestations apart from AI and osteoporosis associated with this disorder. We describe a patient with a cluster of more endocrine diseases. Case: A 44-year-old hispanic female was diagnosed with Allgrove syndrome in the first decade of her life when she was found to have esophageal achalasia, AI, and absence of lacrimation. Physical exam revealed BMI of 18 kg/m2 without dysmorphic features, skin abnormalities, or neurological deficits. Thyroid gland size was within normal limits, and there was no evidence of thyroid eye disease. She had multiple hospitalizations with abdominal symptoms attributed to esophageal stricture and esophagitis resulting in an adrenal crisis each time. During one such hospitalization, she had symptoms suggesting hyperthyroidism including palpitations, weight loss, and heat intolerance. Workup was consistent with Graves’ disease, and she was started on methimazole 5 mg daily with good response. Further evaluation revealed that she became amenorrheic in her 20s. Workup was consistent with premature ovarian failure (POF). A DXA scan revealed very low bone mineral density consistent with osteoporosis (T scores; Hip: -3.8, Fem neck: -3.7, Lumbar Spine: -3.5). She had mild vitamin D deficiency but normal calcium and parathyroid hormone levels. The patient chose osteoporosis-specific treatment over hormonal replacement. Zoledronic acid was chosen considering her history of Heller myotomy and esophageal strictures. She was maintained on hydrocortisone 20 mg daily for her adrenal insufficiency. Lab work: FSH: 148 mIU/ml (3.5 - 12.5)LH: 58.4 mIU/ml (2.4 - 12.5)Estradiol: <5 pg/mL (12.5 - 166)TSH: <0.01 mIU/mL(0.35 - 4.94)T4 Free: 2.45 ng/dL (0.7 - 1.48)TSI %: 412(<140)PTH: 17 pg/mL (15 - 65)Learning points: Allgrove syndrome is a rare autosomal recessive inherited disorder with 70% of the patients developing the classic triad of alacrimia, esophageal achalasia, and AI. Early onset osteoporosis that is not completely explained by glucocorticoid use, has been described. We present a patient with Allgrove syndrome with additional disorders of hyperthyroidism and POF which are known risk factors for osteoporosis. It is unclear if these additional endocrine abnormalities are manifestations of Allgrove syndrome or just coincidental. Further evaluation of known cases of Allgrove syndrome for these disorders can help answer this question. Presentation: 6/3/2024
Medicine
What problem does this paper attempt to address?